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Abstract
Incretin hormone-based therapy in type 2 diabetes has been widely used, and dipepdityl peptidase-4 (DPP-4) inhibitors, which
prevent incretin degradation, have become popular oral hypoglycemic agents. The efﬁcacy of DPP-4 inhibitors varies from
individuals, and factors determining responses to DPP-4 inhibitors have not been fully established. We aimed to investigate whether
genetic variations in glucagon-like peptide (GLP-1) receptor are associated with responses to DPP-4 inhibitors in patients with type 2
diabetes.
Genetic variations of rs3765467 in GLP-1 receptor were explored in 246 patients with type 2 diabetes who received DPP-4
inhibitors treatment for 24 weeks in addition to previous medication. Patients with glycated hemoglobin (HbA1c)> 7% and who were
naive to any DPP-4 inhibitors were enrolled. Responders were deﬁned as those who showed a> 10% reduction in HbA1c after DPP-
4 inhibitor treatment.
DPP-4 inhibitors improved glycemic parameters and lipid proﬁles. Compared to the major genotype (GG), a larger proportion of
patients with the minor allele genotype (GA/AA) were responders (P=0.018), and also showing greater HbA1c reductions (1.3±1.1
vs 0.9±1.2%; P=0.022). This genetic effect remained signiﬁcant even after adjustment for other confounding factors (OR=2.00,
95% CI=1.03–3.89).
Polymorphism in the GLP-1 receptor may inﬂuence DPP-4 inhibitor response. Further studies in larger population will help
determine the association between genetic variation and interindividual differences in DPP-4 inhibitor therapy.
Abbreviations: ANOVA= analysis of variance, BMI= bodymass index, CI= conﬁdence interval, DPP-4= dipepdityl peptidase-4,
GLP-1= glucagon-like peptide,GLP1R=GLP-1 receptor gene, HbA1c= glycated hemoglobin, HDL= high-density lipoprotein, LDL
= low-density lipoprotein, OR = odds ratio, T2DM = type 2 diabetes mellitus.
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Incretin hormones regulate glucose-modulated insulin secretion
from pancreatic b cells.[1] The 2 incretin hormones, glucagon-like
peptide (GLP-1) and glucose-dependent insulinotropic polypep-
tide (GIP), are inactivated by dipeptidyl peptidase-4 (DPP-4), the
peptidase enzyme soon after they secreted from intestinal cells.[2]
Incretins act on G protein-coupled receptors on the pancreatic b
cell membranes to stimulate cyclic adenosine monophosphate
(cAMP) formation, protein kinase A activation, and insulin
secretion.[1] The process of stimulated insulin release is rapid, and
DPP-4 inhibitors prevent degradation of endogenous incretin
hormones, to improve the duration of GLP-1 and GIP activity. In
fact, 6-month DPP-4 inhibitor treatment elevated insulin
secretion and decreased postprandial glucagon-to-insulin ratio
in a clinical study.[3] Additionally, DPP-4 inhibitors also involve a
low risk of hypoglycemia.[4] Although safety concerns for acute
pancreatitis and DPP-4 inhibitor use are controversial, a
population-based case-control study showed that incretin-based
therapy did not increase acute pancreatitis risk.[5]
A number of studies have reported on associations between
speciﬁc genetic variations and glycemic responses obtained with
antidiabetic medications.[6–9] Genetic mutation of the peroxi-
some proliferator-activated receptor (PPAR) g2 was shown to
affect responses to rosiglitazone treatment in patients with type 2
diabetes mellitus.[6] However, DPP-4 inhibitors, to which
responses by T2DM patients vary, the genetic factors are not
fully understood.[10] A 52-week treatment with DPP-4 inhibitor
as add-on therapy in Korean population showed that DPP-4
inhibitor responders had higher basal fasting plasma glucose,
with no effect of age on their response rate.[10] This was in
contrast to another study that was mainly based on Caucasian
population of DPP-4 inhibitor responders characterized older age
with mild fasting hyperglycemia.[11] GLP-1 receptors are
involved in the DPP-4 inhibitor action mechanism, and GLP-1
responses may help predict the efﬁcacy DPP-4 inhibitors.[12] A
recent study reported that DPP-4 inhibitors could activate
incretin receptors and inﬂuence the gut-to-pancreas neural
axis.[2] The efﬁcacy of DPP-4 inhibitors might be affected by
GLP-1 receptor, in that the altered structure or afﬁnity of GLP-1
receptor could determine the difference in responses to DPP-4
inhibitors.
Previously, it was reported that the rs3765467 variant of the
GLP-1 receptor gene (GLP1R) was associated with insulin
secretory response to exogenous GLP-1 in nondiabetic sub-
jects.[13] Therefore, we investigated whether this same variation
in GLP1R could affect T2DM patients’ responses to DPP-4
inhibitors.2. Methods
2.1. Subjects inclusion criteria and study preparation
As the current study was exploratory, proportions of responders
for GA genotype and GG/AA genotype were estimated at 50%
and 70%, respectively, which was modiﬁed from a previous
study.[14] For an allocation rate of each genotype of 1:1 (a error=
0.05, b error=0.20), the total sample size required was
calculated as 186, with 80% statistical power. A total of 246
Korean patients with T2DM were recruited from outpatient
clinics at Yonsei University Severance Hospital, and Seoul
National University Hospital, both located in Seoul, Korea.
Diagnosis of T2DM was deﬁned according to the American
Diabetes Association’s criteria.[15] Study inclusion criteria were2(1) ≥ 20 years-old age; (2) DPP-4 inhibitor naive at baseline; (3)
received DPP-4 inhibitor treatment ≥ 24 weeks; (4) baseline
glycated hemoglobin (HbA1c) > 7%; (5) no hypoglycemic
medication change in the last 6 months. Exclusion criteria were
patients with type 1 diabetes mellitus, pregnant or lactating
women, and patients with missing data on baseline clinical or
biochemical parameters. We used a modiﬁed deﬁnition of
glycemic response according to a previous study.[14] Responders
were deﬁned as those exhibiting a ≥ 10% reduction in HbA1c
values after 24 weeks of DPP-4 inhibitor treatment. The
Institutional Review Board of the Yonsei University College of
Medicine (4-2011-0912, 4-2001-0039), and Seoul National
University Hospital approved this study (0412-138-017, 1205-
130-411). All subjects provided written informed consent.2.2. Metabolic and clinical parameters
Fasting blood glucose level, HbA1c, and lipid proﬁles were
assessed at both baseline and 24 weeks after treatment. Fasting
blood glucose, total cholesterol, triglycerides, high-density
lipoprotein (HDL) cholesterol, and low-density lipoprotein
(LDL) cholesterol were measured after overnight (8-hour)
fasting. Clinical parameters of age, sex, height, weight, duration
of diabetes, and type of DPP-4 inhibitors were collected. The
body mass index (BMI) was calculated using the following
formula: BMI=bodyweight (kg) / height m2.Obesity was deﬁned
as BMI ≥ 25kg/m2.[16]2.3. DNA extraction and resequencing of GLP-1 receptor
gene
Genomic DNA was isolated from peripheral blood lymphocytes
in 246 patients. The polymerase chain reaction (PCR) was
performed to amplify exon 4 on chromosome 6 (forward primer
GCGTATATGTCAGGGGAGGA, reverse primer TTTGTCCA-
GAAAGCATGGTG) and an automated genetic analyzer (Model
3730xl, Applied Biosystems, Foster City, CA) was used to
sequence the sample. All DNA was stored at 4’C in 96-well DNA
storage boxes.2.4. Statistical analysis
Differences between genotype, allele, and responder groups were
tested by the chi-square test for categorical variables or Student’s
t-test for continuous variables. The paired t-test was used to
analyze the changes in glycemic and lipid parameters before and
after treatment. Fisher’s exact test was used if expected cell
frequencies were <5. For an additive model, analysis of variance
(ANOVA) was used to compare the means, followed by post hoc
analysis. Proportions in additive model were analyzed in the
chi-square test. Genotype frequencies were tested for
Hardy–Weinberg equilibrium using the chi-square test. Multi-
variate logistic regression analyses were conducted to assess
independent associations between patient’s responses to DPP-4
inhibitors (dependent variable) and rs3765467 (independent
variable), including covariates. Results were expressed as odds
ratio (OR) and 95% conﬁdence interval (CI). Given that
triglyceride, LDL cholesterol, HDL cholesterol, aspartate
aminotransferase (AST), and alanine transaminase (ALT) values
were not normally distributed, statistical analyses of these values
were conducted on log-transformed data. All statistical analyses
were conducted using IBM SPSS (Version 20.0, IBM Corp.
Armonk, NY). A P value<0.05 was considered statistically
Table 2
Clinical and biochemical characteristics of patients according to
rs3765467 genotype.
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using the G∗power program (Version 3.1.9.2, Erdfelder, Faul, &
Buchner).[17]GG (n=169) GA/AA (n=77) P
Male, N, % 77 (45.6) 44 (57.1) 0.092
Age, y 60.9±11.8 63.5±10.6 0.087
Duration of diabetes, y 9.8±7.5 8.2±6.5 0.140
BMI, kg/m2 26.0±4.0 25.0±3.3 0.075
DPP-4 inhibitors response rate, % 52.7 68.8 0.022
Baseline
Fasting blood glucose, mg/dL 155.9±46.4 154.8±41.1 0.867
HbA1c, % 8.2±1.1 8.2±1.0 0.786
Total cholesterol, mg/dL
∗
167.0±36.8 168.0±34.0 0.846
LDL cholesterol, mg/dL
∗
90.2±29.5 91.8±29.6 0.675
HDL cholesterol, mg/dL
∗
49.0±12.6 46.5±13.2 0.095
Triglyceride, mg/dL
∗
157.1±115.4 157.0±95.3 0.743
BUN, mg/dL 15.9±10.8 16.6±6.9 0.622
Creatinine, mg/dL 0.9±0.3 0.9±0.4 0.203
eGFR, mL/min/1.73 m2 83.6±17.5 83.2±20.9 0.862
AST, IU/L
∗
24.7±13.5 22.8±9.4 0.349
ALT, IU/L
∗
28.8±21.6 26.3±14.8 0.544
After 24 weeks3. Results
3.1. Characteristics of study population
Supplementary Table 1, http://links.lww.com/MD/B369 shows
the allele and genotype distributions of rs3765467 in the study
population. G was the major allele, whereas A was the minor
allele in this group. The genotype distribution did not deviated
from Hardy–Weinberg equilibrium (P=0.939). Table 1 shows
clinical characteristics of the study participants at baseline. The
mean duration of diabetes was 9.3 years, and the HbA1c level
was∼8.2%. After 24weeks of DPP-4 inhibitor add-on treatment,
fasting blood glucose levels and HbA1c values signiﬁcantly
decreased (from 155.5±44.8mg/dL to 133.7±34.7, P<0.001
for fasting blood glucose, and 8.2±1.1% to 7.2±0.9%, P<
0.001 for HbA1c). In addition, total cholesterol and triglyceride
levels also decreased signiﬁcantly (all Ps<0.001).Fasting blood glucose, mg/dL 135.1±32.2 130.2±36.3 0.305
D Fasting blood glucose 20.6±49.1 24.6±36.3 0.516
HbA1c, % 7.3±1.0 6.9±0.7 0.014
D HbA1c 0.9±1.2 1.3±1.1 0.022
Total cholesterol, mg/dL 159.9±19.8 157.7±26.8 0.591
D Total cholesterol 8.2±30.6 11.1±28.7 0.493
LDL cholesterol, mg/dL
∗
102.2±137.2 85.6±24.6 0.578
D LDL cholesterol 13.9±135.1 8.2±22.2 0.193
HDL cholesterol, mg/dL
∗
48.5±12.6 46.3±14.0 0.145
D HDL cholesterol 0.2±8.8 1.2±8.2 0.274
Triglyceride, mg/dL
∗
139.1±74.1 129.7±81.2 0.247
D Triglyceride 24.0±116.7 23.5±59.1 0.973
Data are presented as mean± standard deviation or number, %.
ALT= alanine transaminase, AST= aspartate transaminase, BUN=blood urea nitrogen, eGFR=3.2. Association between GLP1R genetic variants and
DPP-4 inhibitor efﬁcacy
No signiﬁcant differences in baseline fasting blood glucose and
HbA1c were found between patients with GA/AA genotype and
those with GG genotype. However, patients with GA/AA
genotype were associated with a signiﬁcantly greater reduction
of HbA1c levels after DPP-4 inhibitor treatment (variation: 1.3±
1.1% vs 0.9±1.2%; P=0.022) (Table 2).
The proportion of DPP-4 inhibitor responders with GG
genotype (52.7%) was signiﬁcantly lower than that of responders
with GA/AA genotype (68.8%, P=0.018). Regarding theTable 1
Baseline clinical characteristics of study population.
Characteristics Value
Age, y 61.7±11.5
Sex, men/women 107/139
Duration of diabetes, y 9.3±7.2
BMI, kg/m2 25.7±3.8
Fasting blood glucose, mg/dL 155.5±44.8
HbA1c, % 8.2±1.1
Total cholesterol, mg/dL 167.3±35.9
LDL cholesterol, mg/dL 90.7±29.5
HDL cholesterol, mg/dL 48.2±12.8
Triglyceride, mg/dL 158.5±109.3
BUN, mg/dL 16.1±9.7
Creatinine, mg/dL 0.9±0.3
eGFR, mL/min/1.73 m2 83.5±18.7
AST, IU/L 24.1±12.4
ALT, IU/L 28.0±19.7
Type of DPP-4 inhibitor, N, %
Vildagliptin 151 (61.4)
Sitagliptin 82 (33.3)
Linagliptin 9 (3.7)
Saxagliptin 3 (1.2)
Gemigliptin 1 (0.4)
Data are presented as mean± standard deviation or number (%).
ALT= alanine aminotransferase, AST= aspartate aminotransferase, BMI=body mass index, BUN=
blood urea nitrogen, DPP-4=dipeptidyl peptidase-4, eGFR= estimated glomerular ﬁltration rate,
HbA1c=glycosylated hemoglobin, HDL cholesterol=high-density lipoprotein cholesterol, LDL
cholesterol= low-density lipoprotein cholesterol.
estimated glomerular ﬁltration rates, HbA1c=glycated hemoglobin, HDL cholesterol=high-density
lipoprotein cholesterol, LDL cholesterol= low-density lipoprotein cholesterol.
∗
Log transformed.
3subjects’ responses to DPP-4 inhibitors, the responder group
had shorter diabetes duration (8.1±6.4 vs 10.8±8.0 years, P=
0.008) with higher baseline fasting blood glucose level (162.4±
50.2 vs 146.2±34.5mg/dL, P=0.008) and HbA1c (8.5±1.2%
vs 7.8±0.6% P<0.001). The same types of DPP-4 inhibitor were
used in the 2 groups. When further analyzed with the additive
model, only HbA1c levels following treatment reached statistical
signiﬁcance. The amount of HbA1c reduction was marginally
different between the genotypes. However, the proportion of
patients with AA genotype in the study population was only
2.8% (7/246). Compared to patients with G allele, those with an
A allele showed greater reduction in HbA1c levels after 24 weeks
(1.3±1.1% vs 1.0±1.2%, P=0.044). In addition, proportion of
responders was higher in patients with an A allele than those with
a G allele (69.0% vs 55.4%, P=0.021).3.3. Effect of GLP1R genetic variation according to the
baseline blood glucose level
As baseline HbA1c could inﬂuence the response to DPP-4
inhibitors, we stratiﬁed the subjects according to the median
value of basal HbA1c (8.0%) and rs3765467 genotype.
Proportion of DPP-4 inhibitor responders increased stepwise
among the 4 groups, with the highest response rate shown in
subjects with higher baseline HbA1c and GA/AA genotype
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Figure 1. Differences in the response rates to DPP-4 inhibitors according to baseline HbA1c and rs3765467. (A) The proportion of responders according to HbA1c
and rs3765467 genotype, (B) the proportion of responders according to HbA1c and rs3765467 allele. Error bars represent 95% conﬁdence intervals. DPP-4 =
dipepdityl peptidase-4, HbA1c = glycated hemoglobin.
Han et al. Medicine (2016) 95:44 Medicine(91.2%, P<0.001 for trend, Fig. 1A), as well as A allele (89.2%,
P<0.001 for trend, Fig. 1B). Moreover, response rates to DPP-4
inhibitor in patients with higher baseline HbA1c (> 8%) were
determined by rs3765467 variation (P=0.005 for GA/AA
genotype and 0.017 for A allele).
3.4. GLP1R genetic effect on DPP-4 inhibitor efﬁcacy
remained signiﬁcantly in multivariate logistic analysis
Next, we performed multivariate analyses to evaluate
whether this genetic effect remained signiﬁcant, even after
adjustment for other confounding factors. GLP1R variation
remained a signiﬁcant factor affecting the efﬁcacy of DPP-4
inhibitors. Patients with an A allele (GA/AA) showed better
responses to DPP-4 inhibitors than those without (GG).
Compared with GG genotype, GA/AA genotype increased
the likelihood of a response by 200% (Table 3). Furthermore,
patients with an A allele tended to respond better to DPP-4
inhibitors (Table 3).4. Discussion and conclusions
In the current study, we found that variation in GLP1R
(rs3765426) is associated with DPP-4 inhibitor response efﬁcacy.
A larger number of patients with an A allele showed a reduction
in HbA1c, with DPP-4 inhibitor treatment than those without.
This genetic effect remained signiﬁcant after adjustment for other
confounding factors. In addition, as previously reported,
responders to DPP-4 inhibitors had shorter duration of diabetes,
higher fasting blood glucose, and HbA1c at baseline.[10]Table 3
Logistic regression analysis for predicting DPP-4 inhibitor treatment
Patients with GA/AA genotype
Odds ratio 95% CI
Unadjusted 1.99 1.12–3.51 0
Model 1 1.98 1.11–3.52 0
Model 2 1.93 1.01–3.67 0
Model 3 2.00 1.03–3.89 0
Model 1 is adjusted for age and sex.
Model 2 is adjusted for age, sex, diabetes duration, obesity, and baseline fasting blood glucose.
Model 3 is adjusted for age, sex, diabetes duration, and obesity, baseline fasting blood glucose, HDL c
CI= conﬁdence interval, DPP-4=dipepdityl peptidase-4, HDL cholesterol=high-density lipoprotein chol
∗
Log transformed.
4Interestingly, in this study, the proportion of DPP-4 inhibitor
responders increased in relation to GLP1R genotype and higher
baseline HbA1c. However, the association between DPP-4
inhibitor efﬁcacy and baseline HbA1c remains controversial.
One cohort study reported that lower baseline HbA1c was linked
to a good response in DPP-4 inhibitor treatment,[18] whereas
others have shown that a higher baseline HbA1c could predict a
greater DPP-4 inhibitor response.[10,19] In a meta-analysis that
compared HbA1c changes according to baseline HbA1c value,
the amount of reduction increased to 0.83%, with a baseline
HbA1c of 8.5%.[19] In the current study, a greater reduction of
HbA1c (1.3%) was observed in GA/AA genotype population
with similar baseline HbA1c (8.2%), suggesting a role for
GLP1R variation in the effect of DPP-4 inhibitors.
Many investigators have found the concepts of genetic
variation and antidiabetic medication efﬁcacy to be quite
attractive. For PPAR agonists, polymorphisms of PPAR, adipose
tissue, adiponectin, and cholesterol synthesis have all been shown
to have an impact on drug potency.[6–8,20,21] Genetic variants in
transcription factors have also been shown to inﬂuence
pharmacokinetics and pharmacodynamics of metformin.[22]
Although the correlation between DPP-4 inhibitors and genetic
variation is controversial, our study would support such a
correlation with the A allele of rs3765467.
Previously, we reported no signiﬁcant association between
genetic variations in DPP4 itself, and patient responses to DPP-4
inhibitors.[23] On the other hand, an association between
interleukin-6 polymorphism and DPP-4 inhibitor response has
been reported.[24] Recent preclinical studies have shown associa-
tion between DPP-4 inhibitors and incretin receptors.[25,26] Sinceresponse.
Patients with A allele
P Odds ratio 95% CI P
.018 1.80 1.09–2.97 0.022
.020 1.78 1.07–2.94 0.026
.046 1.82 1.10–3.04 0.022
.042 1.97 1.15–3.37 0.014
holesterol
∗
, and triglycerides
∗
.
esterol.
Han et al. Medicine (2016) 95:44 www.md-journal.comadministration of DPP-4 inhibitor to incretin receptor knockout
mice did not improve glycemic parameters, these ﬁndings suggest
the importance of incretin receptor in glucoregulatory actions of
DPP-4 inhibitors.
Two possible functional mechanisms of genetic effects have
been suggested:[27] (1) GLP-1 receptor enhances cAMP signaling,
and (2) GLP-1 receptor alters pancreatic b cell apoptosis or
proliferation. Several papers reported that variation in GLP1R
could regulate intracellular postreceptor signaling.[28–31] More-
over, GLP1R variant is reported to be able to alter receptor
binding afﬁnity.[31,32] Rs3765467 is a nonsynonymous mutation
in which amino acid arginine is replaced by glutamine at Exon 5
position 131 (R131Q) of the GLP-1 receptor, and it was also
reported to be linked with cAMP signaling in oxynotomodu-
lin.[32] A recent human study showed that rs3765467 had a very
profound insulinotropic effect in response to infused GLP-1
agonist.[13] Given this point, a GLP1R variation, especially
rs3765467, could be a candidate for determining the efﬁcacy of
DPP-4 inhibitors. Meanwhile, the degree of DPP-4 inhibitor
efﬁcacy could be explained by ethnicity.[33] Compared to non-
Asians, Asians exhibit a higher capacity to respond to DPP-4
inhibitor treatment. In a meta-analysis study, lower BMI in
Asians, which could be related to insulin sensitivity, was referred
to as a primary factor.[33] According to an international database,
minor allele frequency (MAF) for rs3765467 is reported to occur
in up to 36% of Asians, which is relatively high compared to
other ethnicities.[34] In the current study, the MAF was 17.1%.
The relatively high A allele frequency in Asians may account for
the better response in these populations.
A recent Taiwanese study showed that GLP-1 analog response
was not affected by GLP1R variation.[35] The study enrolled 36
patients with poorly controlled hyperglycemia and treated them
with a 6-day continuous subcutaneous insulin infusion and
exenatide, a GLP-1 analogue. Patients with rs3765467 minor
allele genotype showed a signiﬁcant reduction in the plasma
glucose level before adjustment. The small sample size might
account for the statistical insigniﬁcance after adjustment. In
contrast, our study showed response rates for GA and GG/GA
genotypes of 52.7% and 68.8%, which were comparable to our
estimation. In addition, the statistical power reached 83%, which
slightly exceeded the 80% we had predicted.
Meanwhile, there are some limitations to our study. First, we
could not assess insulin sensitivity or pancreatic beta cell function
due to a lack of information on C peptides and insulin levels.
However, a previous study showed that the minor allele of
rs3765467 is associated with a 2-fold increase in insulin secretion
in response to exogenous GLP-1 infusion.[13] Second, types and
dose of DPP-4 inhibitors were not controlled in the study
population. Despite uncontrolled medication, difference in the
types of DPP-4 inhibitor between responder and nonresponder
was insigniﬁcant. Third, physical activity and dietary changes
that could improve hyperglycemia were not evaluated in the
current study. Nevertheless, our data suggest for the ﬁrst time
that GLP1R variation can affect patient response to DPP-4
inhibitors. Finally, since the current studywas an exploratory and
observation study, we could not conﬁrm the actual or speciﬁc
mechanism of GLP1R and DPP-4 inhibitor response.
In conclusion, the present study shows that DPP-4 inhibitor
treatment reduces blood glucose levels during a 24-week period,
and that a greater number of DPP-4 inhibitor responders carry
either the GA/AA genotype or an A allele. In multivariate
regression analysis, both GA/AA genotype and an A allele for
GLP1R were consistently associated with DPP-4 inhibitor5response. This suggests that variation in GLP1R (rs3765467)
can inﬂuence DPP-4 inhibitor efﬁcacy. Further studies in a large
population are warranted to determine the mechanisms of DPP-4
inhibitor response in GLP1R. Moreover, it would be interesting
to identify the genetic differences related to DPP-4 inhibitor
response among other ethnic groups. This ﬁnding could be
clinically relevant in that one could potentially anticipate DPP-4
inhibitor responses before administering thereof.
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